Demars Financial Group LLC Acquires Shares of 912 Johnson & Johnson (NYSE:JNJ)

Demars Financial Group LLC acquired a new stake in Johnson & Johnson (NYSE:JNJ) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 912 shares of the company’s stock, valued at approximately $128,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Sofos Investments Inc. grew its position in Johnson & Johnson by 172.0% during the 1st quarter. Sofos Investments Inc. now owns 1,148 shares of the company’s stock worth $33,000 after purchasing an additional 726 shares in the last quarter. Altshuler Shaham Ltd purchased a new position in Johnson & Johnson during the 1st quarter worth approximately $35,000. Lake Point Wealth Management grew its position in Johnson & Johnson by 144.4% during the 1st quarter. Lake Point Wealth Management now owns 286 shares of the company’s stock worth $38,000 after purchasing an additional 169 shares in the last quarter. Islay Capital Management LLC purchased a new position in Johnson & Johnson during the 2nd quarter worth approximately $42,000. Finally, Lion Street Advisors LLC purchased a new position in Johnson & Johnson during the 1st quarter worth approximately $45,000. 67.44% of the stock is currently owned by institutional investors.

In other news, EVP Kathryn E. Wengel sold 16,115 shares of the company’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $153.52, for a total transaction of $2,473,974.80. Following the completion of the transaction, the executive vice president now owns 66,658 shares of the company’s stock, valued at $10,233,336.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Ashley Mcevoy sold 29,000 shares of the stock in a transaction dated Tuesday, July 28th. The shares were sold at an average price of $147.47, for a total transaction of $4,276,630.00. Following the completion of the sale, the executive vice president now owns 21,682 shares of the company’s stock, valued at approximately $3,197,444.54. The disclosure for this sale can be found here. 0.27% of the stock is owned by insiders.

Several equities analysts have recently commented on JNJ shares. Independent Research upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and boosted their price target for the company from $161.00 to $164.00 in a report on Monday, July 20th. SVB Leerink restated an “outperform” rating on shares of Johnson & Johnson in a report on Wednesday, July 15th. ValuEngine upgraded shares of Johnson & Johnson from a “sell” rating to a “hold” rating in a report on Monday, August 3rd. Cantor Fitzgerald restated a “buy” rating and set a $168.00 price target on shares of Johnson & Johnson in a report on Monday, August 3rd. Finally, Citigroup boosted their price target on shares of Johnson & Johnson from $165.00 to $170.00 and gave the company a “buy” rating in a report on Friday, July 17th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and eleven have assigned a buy rating to the stock. Johnson & Johnson currently has a consensus rating of “Buy” and an average target price of $163.00.

NYSE:JNJ traded down $0.49 during trading hours on Wednesday, reaching $148.40. The company’s stock had a trading volume of 4,153,046 shares, compared to its average volume of 8,454,454. The company has a market cap of $390.71 billion, a price-to-earnings ratio of 21.70, a price-to-earnings-growth ratio of 3.27 and a beta of 0.68. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.25 and a quick ratio of 0.99. Johnson & Johnson has a one year low of $109.16 and a one year high of $157.00. The business’s 50-day moving average is $149.33 and its 200-day moving average is $144.21.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Thursday, July 16th. The company reported $1.67 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.50 by $0.17. The firm had revenue of $18.34 billion during the quarter, compared to analyst estimates of $17.73 billion. Johnson & Johnson had a net margin of 22.69% and a return on equity of 35.21%. The business’s revenue was down 10.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.58 EPS. On average, sell-side analysts predict that Johnson & Johnson will post 7.85 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th were given a dividend of $1.01 per share. This represents a $4.04 dividend on an annualized basis and a yield of 2.72%. The ex-dividend date of this dividend was Monday, August 24th. Johnson & Johnson’s dividend payout ratio is 46.54%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Featured Story: What is included in the gross domestic product?

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.